A comprehensive view of novavax inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Novavax extends partnership with Siegfried until end of 2023 for aseptic fill & finish of Novavax’s coronavirus vaccine Nuvaxovid; fill/finish completed at Siegfried’s manufacturing plant in Hameln, Germany
Published: September 28, 2022 by Contify Life Science News
JPMorgan downgrades Novavax to underweight from neutral and slashes target by more than US$100 to US$27 following company halving its full-year 2022 revenue forecast and warning that it doesn't expect to sell any more Covid vaccines in US in 2022
Published: September 23, 2022 by Jackson Progress-Argus
President Biden’s statement that the COVID-19 pandemic is over results in shares of Moderna, BioNTech, Novavax falling as much as 9% in early trading Monday; COVID-19 vaccine market may start to resemble flu vaccine market valued at US$5.0B annually
Published: September 20, 2022 by CE NAFTA 2.0 Newswire
Novavax receives FDA emergency use authorization for its adjuvanted COVID-19 vaccination for adolescents 12 through 17 years of age; vaccine approved in two-dose primary series to prevent COVID-19
Published: August 23, 2022 by SeeNews Pharmaceuticals
Novavax seeks FDA approval for its protein-based NVX-CoV2373 COVID-19 vaccine for use as a booster dose in adults; the FDA approved the vaccine for emergency use in the US in July
Published: August 17, 2022 by SeeNews Pharmaceuticals

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count